Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE−/− mice by SC-435
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Blocking intestinal bile acid absorption by inhibiting the apical sodium codependent bile acid transporter (ASBT) is a target for increasing hepatic bile acid synthesis and reducing plasma LDL cholesterol. SC-435 was identified as a potent inhibitor of ASBT (IC50 = 1.5 nM) in cells transfected with the human ASBT gene. Dietary administration of 3 mg/kg to 30 mg/kg SC-435 to apolipoprotein E-/- (apoE-/-) mice increased fecal bile acid excretion by >2.5-fold. In vivo inhibition of ASBT also resulted in significant increases of hepatic mRNA levels for cholesterol 7alpha-hydroxylase and HMG-CoA reductase. Administration of 10 mg/kg SC-435 for 12 weeks to apoE-/- mice lowered serum total cholesterol by 35% and reduced aortic root lesion area by 65%. Treatment of apoE-/- mice also resulted in decreased expression of ileal bile acid binding protein and hepatic nuclear hormone receptor small heterodimer partner, direct target genes of the farnesoid X receptor (FXR), suggesting a possible role of FXR in SC-435 modulation of cholesterol homeostasis. In dogs, SC-435 treatment reduced serum total cholesterol levels by </=12% and, in combination with atorvastatin treatment, caused an additional reduction of 25%. These results suggest that specific inhibition of ASBT is a novel therapeutic approach for treatment of hypercholesterolemia resulting in a decreased risk for atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Cited by
Bile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
Dawson, P. A., Lan, T., & Rao, A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900012-jlr200 · Cited by 680
Intestinal transport and metabolism of bile acids
Dawson, P. A., & Karpen, S. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r054114 · Cited by 598
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 504
Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications
Alrefai, W. A., & Gill, R. K. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9289-1 · Cited by 500
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 393
Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT
Hu, N.-J., Iwata, S., Cameron, A. D., & Drew, D. (2011) · Nature · doi:10.1038/nature10450 · Cited by 266
Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review
Chambers, K. F., Day, P. E., Aboufarrag, H. T., & Kroon, P. A. (2019) · Nutrients · doi:10.3390/nu11112588 · Cited by 262
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Rao, A., Kosters, A., Mells, J. E., Zhang, W., Setchell, K. D. R., Amanso, A. M., Wynn, G. M., Xu, T., Keller, B. T., Yin, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4823 · Cited by 211
“to BAs (22, 41), so it is intriguing to speculate that inhibition of ASBT may provide a means to improve features of hepatic lipotoxicity and metabolic syndrome while alleviating some atherosclerotic risk factors.”
BackgroundSelf-citationThe Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids
Cao, W., Kayama, H., Chen, M. L., Delmas, A., Sun, A., Kim, S. Y., Rangarajan, E. S., McKevitt, K., Beck, A. P., Jackson, C. B., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.012 · Cited by 102
“Although BA sequestration alters liver metabolism (Bhat et al., 2003), both the selective regulation of Mdr1-deficient siLP Teff cell function and the similar pharmacodynamic effects of CME treatment and Asbt ablation suggest that CME acts locally in this model to prevent the pathogenic interaction between Mdr1-defici…”
BackgroundMethodCingolani, F., Liu, Y., Shen, Y., Wen, J., Farris, A. B., & Czaja, M. J. (2022) · Hepatology Communications · doi:10.1002/hep4.1867 · Cited by 18
Wang, Q., Peng, J., Tian, Y., Li, J., Cai, J., & Qin, W. (2025) · Current Microbiology · doi:10.1007/s00284-024-03974-5 · Cited by 5
“Excretion of numerous BAs has been shown to limit the development of atherosclerosis in mice with excessive intake of cholesterol and reduce LDL-C levels [27].”
Metadata
- Authors
- Bhat, B. G., Rapp, S. R., Beaudry, J. A., Napawan, N., Butteiger, D. N., Hall, K. A., Null, C. L., Luo, Y., & Keller, B. T.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 44
- Issue
- 9
- Pages
- 1614-1621
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2114000516
- Cited by
- 99
- References
- 3
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.